Which donor or graft source should you choose for the strongest GVL? Is there really any difference

Research output: Contribution to journalReview article

6 Scopus citations


Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.

Original languageEnglish (US)
Pages (from-to)293-296
Number of pages4
JournalBest Practice and Research: Clinical Haematology
Issue number3
StatePublished - Sep 2013



  • GVL, graft-versus-leukemia
  • HCT hematopoietic cell transplantation
  • HLA-matched donors
  • UCB, umbilical cord blood
  • bone marrow
  • graft source
  • haploidentical
  • peripheral blood
  • relapse

Cite this